|
|
 |
|
Viewing report
|
|
|
|
Forecast Insight: Antihypertensives New fixed dose combinations unable to stem the tide of patent expiries
Datamonitor, July 2009, Pages: 181
Following the patent expiries of ARBs Datamonitor expects antihypertensives sales in the seven major markets to record sales of $29.5 billion in 2018, a drop of over $6 billion compared to 2008. With no promising novel pipeline agents, pharmaceutical companies have little choice but to adopt line extension life cycle management strategies introducing a number of new fixed dose combinations.
Scope
- Description of the competitive landscape in antihypertensives across seven major markets with market definition and overview.
- Definition of the unmet need in the antihypertensives market.
- Event-driven updated sales forecasts for 2009-18 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
- Analysis of major events and brand dynamics affecting the hypertension market.
Highlights of this title
The antihypertensive market is declining. The market is mature and does not present an attractive opportunity for R&D expenditure; consequently Big Pharma are shying away from the pursuit of novel mechanisms of action in favor of developing more efficacious combination therapies.
Cozaars and Diovans patent expiries in the US are expected to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets, are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market.
Novartis have failed to strengthen its position in the antihypertensives arena with its new renin inhibitor Tekturna and Exforge is expected to face a number of competitive alternatives. More fixed dose combinations from all major players are soon expected to enter. Those agents however will be restricted to a niche population with limited growth.
Key reasons to purchase this title
- Quantify the future size of the antihypertensives market and identify opportunities for new products.
- Learn how recent changes related to product expiries will shape the antihypertensives market.
- Understand the barriers to uptake for novel antihypertensive agents, and the need for paradigm shift in clinical trial design.
Customers who bought this item also bought
Forecast Insight: Antihypertensives - Key Patent Expiries Prevent Market Growth
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
Commercial Insight: Antihypertensives - New Challenges for a Maturing Market
Antihypertensives - Two Years to Shape the Market?
Commercial Insight: Antihypertensives - Can Manufacturers Maintain Value?
Antihypertensives - Weak Pipeline Leaves Innovation to Novartis
Competitor Analysis: Antihypertensives
Pipeline Insight: Antihypertensives - Together We Stand, Divided We Fail
Report on Antihypertensive Drug Market
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming Patent Expiries Limit Market Growth
Generic Drug Market in Canada
|
|
|
|
